Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $21.21 USD
Change Today -0.17 / -0.80%
Volume 27.7K
EXAC On Other Exchanges
As of 8:10 PM 06/1/15 All times are local (Market data is delayed by at least 15 minutes).

exactech inc (EXAC) Key Developments

Exactech Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Revenue Guidance for the Second Quarter Ending June 30, 2015; Provides Revenue Guidance for the Year 2015

Exactech Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net sales of $61,376,000 against $63,258,000 a year ago. Income from operations was $6,066,000 against $6,611,000 a year ago. Income before income taxes was $5,592,000 against $6,604,000 a year ago. Net income was $4,112,000 against $4,198,000 a year ago. Diluted earnings per share were $0.29 against $0.30 per share a year ago. For the year 2015, the company’s revenue guidance to $248 million to $254 million and its diluted EPS target to $1.18 to $1.24. The company expects the tax rate to be 33% to 34% for the balance of the year. For the second quarter ending June 30, 2015, the company anticipates revenues of $61 to $63 and diluted EPS of $0.26 to $0.28. The company continues to expect gross margins to decrease approximately 50 basis points on a comparative quarter basis due to the continued impact of pricing, as well as the impact of foreign exchange rates where they currently reside. The company expects to experience a compression of operating margin in the second quarter, primarily due to the impact of the FX rate.

Exactech Inc. Provides Earnings Guidance for the First Quarter Ended March 31, 2015

Exactech Inc. provides earnings guidance for the first quarter ended March 31, 2015. The company expects revenues for the quarter to be $61.4 million and diluted earnings per share for the quarter to be in the range of $0.29 - $0.30.

Exactech Inc. to Report Q1, 2015 Results on Apr 28, 2015

Exactech Inc. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on Apr 28, 2015

Exactech Inc., Q1 2015 Earnings Call, Apr 29, 2015

Exactech Inc., Q1 2015 Earnings Call, Apr 29, 2015

Exactech, Inc. Unveils New Bone and Joint Restoration Products

Exactech Inc. has unveiled new bone and joint restoration products including hip, knee, shoulder and spine surgical solutions. Exactech Knee product family includes the next generation of ExactechGPS Guided Personalised Surgery, which merges sophisticated technology with innovative instrumentation for a real-time, patient-specific solution in total knee arthroplasty. Customized for surgeon preferences, ExactechGPS offers personalised workflow options for reproducibility and efficiency and is surgeon-controlled through a compact, stand-alone system that is designed to integrate into any surgical environment. A new cementless fixation solution for total knee arthroplasty, Optetrak Logic Porous femoral component strikes the optimal balance between material strength, pore size and porosity. In an ovine study, the system's proprietary material comprised of a unique 3-D structural lattice of irregular shaped particles demonstrated higher bone in-growth, greater strength and greater fixation than traditional porous-beaded coating. The Exactech Hip portfolio expands its scope of solutions with the introduction of the Alteon Tapered Wedge Femoral Stem. This next generation, single-taper, wedge-style femoral stem incorporates specific design features to achieve immediate axial and rotational mechanical stability between the medial and lateral cortices of the femoral canal. Exactech Hip portfolio also include: the continued rollout of the Alteon Neck Preserving Femoral Stem which was developed for primary femoral solutions. Unlike traditional stems, this product is a conservative treatment option designed for maintaining the maximum amount of femoral bone; and InteGrip which is a three-dimensional, porous ingrowth material that was developed for acetabular cups in revision and complex primary procedures. The Equinoxe Shoulder System celebrates 10 years of engineering solutions to solve clinical challenges and improve patient outcomes with the introduction of two additions to its wide range of glenoid options. The Posterior Augment Cage Glenoid is designed to provide immediate fixation for anatomic TSA. The Superior/Posterior Augment Baseplate is a new augment designed to correct for superior and posterior wear during challenging reverse procedures. Implant removal solutions include the AcuDriver Automated Osteotome System, an air-driven impact handpiece with precision osteotomes in various sizes for use in revision surgeries. Exactech's InterSpace hip, knee and shoulder spacers are used in two-stage infected revision procedures and provide orthopedic surgeons with the only preformed spacer on the market with a documented clinical history. Exactech recognizes the growing importance of biologic solutions for orthopaedics and is proud to feature Optecure, an engineered bone graft for reconstruction of the spine, pelvis and extremities. Its room temperature convenience facilitates rapid mixing with buffer solution or blood. Optecure and Optecure+ccc can be used with autologus bone and bone marrow.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXAC:US $21.21 USD -0.17

EXAC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aerovironment Inc $25.65 USD -0.20
Alphatec Holdings Inc $1.36 USD +0.01
API Technologies Corp $2.25 USD +0.09
Mercury Systems Inc $13.73 USD +0.08
RTI Surgical Inc $6.56 USD +0.09
View Industry Companies

Industry Analysis


Industry Average

Valuation EXAC Industry Range
Price/Earnings 18.4x
Price/Sales 1.2x
Price/Book 1.4x
Price/Cash Flow 8.9x
TEV/Sales 1.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXACTECH INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at